






100

*Clr/Clr/MASP-1/MASP-2/MASP-3*



*Fig. 2A.*



*Fig. 2B.*




Fig.3.




Fig.4.




Fig. 5A.




Fig. 5B.




Fig.5C.




Fig.6.






Fig. 7.


10/76

*Fig. 8A.*


11/76

*Fig. 8B.*

12/76

*Fig.8C.*

13/76

*Fig.9.*




Fig. 10.

Binding of AbD Ab #40 & #60 to rat MASP2 polypeptides




Fig. 11.




Fig. 12.




Fig. 13A.




Fig.13B.








Fig.14.


20/76

*Fig.15A.**Fig.15B.*



21/76

*Fig.16A.**Fig.16B.*


22/76

*Fig.17.*



23/76

*Fig.18.**Fig.19.*


24/76

*Fig.20.*

25/76

*Fig.21.**Fig.22.*

26/76

*Fig.23.*

27/76




Fig.24A.




Fig.24B.




Fig. 25A.




Fig.25B.








Fig.25C.

32/76

*Fig.26A.**Fig.26B.*

33/76

*Fig.27A.**Fig.27B.*

34/76




Fig.28A.






Fig.28B.

35/76





*Fig.28C.*




*Fig.28D.*

36/76


*Fig.29A.**Fig.29B.*

37/76



*Fig.30*

38/76

*Fig.31.*




Fig.32A.




Fig.32B.

Survival after *N. meningitidis* Serogroup A Z2491 infection




Fig.33.






Fig.34.


42/76

*Fig.35.*

43/76

*Fig.36.*

44/76

*Fig.37.*






Fig. 38.

46/76


*Fig.39.*

47/76


Haemolysis of mannan-coated Murine RBC by human serum

*Fig.40.*

48/76

*Fig.41.*

49/76

*Fig.42.*

50/76





Fig. 43.


51/76

Time to onset of microvascular occlusion  
following LPS injection (Schwarzman model)




*Fig.44.*


52/76

*Fig.45.*


53/76

*Fig.46.*


54/76

*Fig.47.*


55/76

**Fig.48.**


56/76

*Fig.49.*


57/76

*Fig.50.*


58/76

*Fig.51.*


59/76

*Fig.52.*


60/76

*Fig.53A.*


61/76

*Fig.53B.*


62/76

*Fig.53C.*


63/76

*Fig.54.*


64/76

*Fig.55A.*


65/76

*Fig.55B.*

66/76


**Fig.56.**

67/76

**Fig.57.**

68/76


Platelet Count Change from Baseline over Time



*Fig.58.*

69/76

## LDH Change from Baseline over Time

**Fig.59.**

70/76

## Change in Haptoglobin over Time



**Fig.60.**


FIGURE 61



# 72/76

## FIGURE 62A


### Compassionate Use Patient # 1: CREATININE



# 73/76

## FIGURE 62B


### Compassionate Use Patient # 1: HAPTOGLOBIN



74/76

FIGURE 62C


Compassionate Use Patient # 1: HEMOGLOBIN



# 75/76

## FIGURE 62D

### Compassionate Use Patient # 1: LDH



# 76/76

## FIGURE 62E

### Compassionate Use Patient # 1: PLATELETS

